Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 7/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9348641 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL440314 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL4606854 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL7927733 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL1820900 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL23026283 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL7919319 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL8614599 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL15353147 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB | |
| SCHEMBL8586429 | 1.00 | LGALS8 (0.46) | LGALS8OGASLC2A1MAPK1PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157138-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA | 2020-05-21 | — | — | US | disclosed |
| US-20040208883-A1 | Method for preparing ester linked peptide-carbohydrate conjugates | ISIS INNOVATION LIMITED (GB) | 2004-10-21 | — | — | US | disclosed |
| EP-1414988-A1 | METHOD FOR PREPARING ESTER LINKED PEPTIDE-CARBOHYDRATE CONJUGATES | ISIS INNOVATION LIMITED (GB) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003014371-A1 | METHOD FOR PREPARING ESTER LINKED PEPTIDE-CARBOHYDRATE CONJUGATES | ISIS INNOVATION LIMITED (GB) | 2003-02-20 | — | — | WO | disclosed |
| EP-0708781-B1 | A 3 ADENOSINE RECEPTOR AGONISTS | USA (US) | 2001-10-04 | — | — | EP | disclosed |
| US-5773423-A | XANTHINE RIBOSIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-06-30 | — | — | US | disclosed |
| EP-0708781-A1 | A 3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002604-A1 | A3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157138-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE ANALOGUES | NAMPT, NNT, NNMT | LGALS8 3581/4885OGA 1473/4885SLC2A1 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.